Glaucoma doesn’t care about your calendar. It doesn’t care that you’ve got dinner plans, a quarterly earnings call, or a bucket list that still has half the world left unchecked. It sneaks in quietly, presses on the optic nerve, and before you know it, vision starts slipping away. For decades, the medical playbook for this thief of sight has been drops, stents, or more invasive surgery, each with tradeoffs that make patients feel like they’re choosing the least bad option. Then along comes Iantrek, Inc., a company that looked at the traditional hardware-heavy approaches and said, no thanks, we’re going to build a biologic future instead.
Founded in 2019 by Tsontcho “Sean” Ianchulev, MD, MPH, a Harvard-trained physician-executive who helped usher Lucentis through the FDA and has more ophthalmic patents than some companies have employees, Iantrek has been busy proving that bio-interventional surgery is not just a buzzword but the next chapter in glaucoma care. From White Plains, New York, with an R&D hub in Providence, Rhode Island, the company has developed a pipeline of biologic grafts and precision tools that tap both trabecular and uveoscleral outflow pathways. Translation: they’ve built a biologic key for every natural lock in the eye.
At the center of this push is AlloFlo Uveo, the first allogeneic biologic spacer designed to enhance the uveoscleral pathway without leaving behind permanent metal or plastic. More than 3,000 procedures later, including over 2,000 in the past year alone, the clinical data is loud and clear. Two years of published results in Ophthalmology Science show a 34% reduction in intraocular pressure, more than 60% fewer medications, and nearly three-quarters of patients achieving a 20% or greater IOP reduction. And here’s the kicker: not a single serious product-related adverse event reported. That’s not incremental progress, that’s a new baseline.
Investors have taken note. Iantrek just closed a $42 million Series C financing round led by U.S. Venture Partners, with strong participation from new investor aMoon Fund and returning backers Visionary Ventures, Sectoral Asset Management, Radius Special Situations Fund, and Civilization Ventures. That brings total funding to roughly $68 million, enough firepower to launch AlloFlo Uveo into full U.S. commercialization this fall during the American Academy of Ophthalmology meeting. The money will also scale manufacturing, expand early access programs, and push forward the pipeline with next-gen products like AlloSert Uveo, CanaloFlo, and the C.Rex system.
Leadership matters in a market this crowded. Adam Szaronos, who took over as CEO in February 2025 after successfully leading Trukera Medical through its acquisition by Bausch + Lomb, is steering commercialization with nearly two decades of ophthalmic experience and an MIT Sloan MBA to match. Dr. Sean Ianchulev remains Chairman and CMO, bringing both scientific vision and a track record of building companies that matter. With board members like Casey Tansey from USVP, Todd Sone from aMoon, and Marc-Andre Marcotte from Sectoral, the governance bench is as strong as the technology pipeline.
The market opportunity is not a rounding error. The MIGS device space is the fastest-growing segment in ophthalmic surgery, topping $500 million in annual U.S. sales with a CAGR north of 20 percent. Global projections have the MIGS market at $5.1 billion by 2030. Iantrek is not just positioning itself to grab share; it’s redefining what counts as minimally invasive by making biologics the standard instead of the exception. For the 2.5 million eyes in the U.S. that are running out of runway with existing MIGS options, that’s not just another treatment, it’s a reset button.
Glaucoma has always been a marathon fought in slow motion, but with this Series C and the commercial launch of AlloFlo Uveo, Iantrek is turning the pace up. Congrats to the full team on raising the kind of round that doesn’t just fuel operations but signals to the market that bio-interventional surgery isn’t coming someday, it’s here. Investors aren’t just writing checks; they’re betting on a future where biologics replace hardware and patients keep more of their sight, for longer.
